ReviewThe Kaohsiung journal of medical sciences2025
Aptasensor-based point-of-care detection of cardiac troponin biomarkers for diagnosis of acute myocardial infarction.
Review in The Kaohsiung journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- [Polydimethylsiloxane microfluidic aptasensor： opening a new era of biomarker point-of-care testing].Se pu = Chinese journal of chromatography · 2026Review
- Portable Point-of-Care Diagnosis Platforms and Emerging Predictive Biomarkers for Rapid Detection of Severe Dengue Viral Infection.ACS sensors · 2025Review
- Aptasensor-based point-of-care detection of cardiac troponin biomarkers for diagnosis of acute myocardial infarction.The Kaohsiung journal of medical sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Acute myocardial infarction (AMI) represents a critical health challenge characterized by a significant reduction in blood flow to the heart, leading to high rates of mortality and morbidity. Cardiac troponins, specifically cardiac troponin I and cardiac troponin T, are essential proteins involved in cardiac muscle contraction and serve as vital biomarkers for the diagnosis of AMI. Aptasensors utilize synthetic aptamers or peptides with high affinity for specific biomarkers and offer a promising approach for integration into portable, user-friendly point-of-care (POC) applications. This review explores recent advances in POC aptasensor-based platforms for the rapid detection of cardiac troponin biomarkers. Furthermore, this review addresses current challenges and potential future directions in the development of aptasensor. Also, it highlights their potential to improve timely and accurate diagnosis in clinical and emergency settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.